Stockscreener 앱 받기
2.04
0.97%
-0.02
전일 마감가:
$2.06
열려 있는:
$2.07
하루 거래량:
394.69K
Relative Volume:
0.53
시가총액:
$164.06M
수익:
$63.63M
순이익/손실:
$10.62M
주가수익비율:
40.80
EPS:
0.05
순현금흐름:
$-8.64M
1주 성능:
-1.45%
1개월 성능:
+12.71%
6개월 성능:
+42.66%
1년 성능:
-5.99%
1일 변동 폭
$2.02
$2.0855
1주일 범위
$1.97
$2.135
52주 변동 폭
$1.32
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
명칭
Protalix BioTherapeutics Inc.
전화
972 4 988 9488
주소
2 Snunit Street, Science Park PO Box 455, Karmiel
PLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.04 | 165.67M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-17 | 재확인 | Rodman & Renshaw | Buy |
| 2016-04-04 | 개시 | Rodman & Renshaw | Buy |
| 2015-04-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2014-11-12 | 재확인 | R. F. Lafferty | Buy |
| 2014-01-24 | 개시 | R. F. Lafferty | Buy |
| 2012-05-02 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | 재확인 | Oppenheimer | Outperform |
| 2012-04-30 | 다운그레이드 | Auriga | Buy → Hold |
| 2011-10-13 | 개시 | Morgan Joseph | Hold |
| 2011-03-17 | 다운그레이드 | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | 재확인 | Oppenheimer | Outperform |
| 2010-10-14 | 재확인 | UBS | Buy |
| 2009-12-02 | 재확인 | Hapoalim | Outperform |
| 2009-09-22 | 개시 | Canaccord Adams | Buy |
| 2009-09-02 | 개시 | Hapoalim | Outperform |
| 2008-12-01 | 재확인 | Oppenheimer | Outperform |
| 2008-03-11 | 개시 | UBS | Buy |
| 2007-11-20 | 개시 | CIBC Wrld Mkts | Sector Outperform |
모두보기
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
Aug Action: Will Protalix BioTherapeutics Inc benefit from government policy - baoquankhu1.vn
Aug Selloffs: What is Protalix BioTherapeutics Inc. s 5 year growth outlookJuly 2025 Earnings & Daily Profit Focused Screening - bollywoodhelpline.com
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Why Protalix BioTherapeutics Inc. (DE) stock remains stableJuly 2025 Technicals & Risk Adjusted Swing Trade Ideas - Улправда
Will Protalix BioTherapeutics Inc. (PBDA) stock outperform Dow JonesJuly 2025 Big Picture & Short-Term High Return Strategies - Улправда
Can Protalix BioTherapeutics Inc. stock hit analyst price targetsJuly 2025 WrapUp & Reliable Intraday Trade Plans - Улправда
Will Protalix BioTherapeutics Inc. stock gain from strong economyStop Loss & Target Return Focused Stock Picks - Улправда
Is Protalix BioTherapeutics Inc. (DE) stock dividend growth reliableMarket Performance Recap & High Conviction Trade Alerts - Улправда
Is Protalix BioTherapeutics Inc. (PBDA) stock a safe buy pre earningsJuly 2025 Short Interest & Fast Moving Trade Plans - Улправда
Will Protalix BioTherapeutics Inc. (PBDA) stock sustain dividend payoutsPortfolio Value Report & Daily Chart Pattern Signal Reports - Улправда
Is Protalix BioTherapeutics Inc. (PBDA) stock among top earnings playsWeekly Investment Report & Stepwise Trade Signal Implementation - Улправда
What technical charts say about Protalix BioTherapeutics Inc. stock2025 Support & Resistance & Risk Managed Investment Signals - Улправда
How Low Can Protalix BioTherapeutics Stock Really Go? - Trefis
Why Protalix BioTherapeutics Inc. (DE) stock benefits from AI revolution2026 world cup usa national team qualification young talents pressing system expert forecast preview - Улправда
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy By Investing.com - Investing.com Nigeria
PLX: Secarna’s antisense oligonucleotide discovery collaboration - MSN
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline - Proactive financial news
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy - Investing.com
Protalix BioTherapeutics, Inc. Provides 2026 Strategic Update - TradingView — Track All Markets
Protalix BioTherapeutics Letter to Stockholders - Nasdaq
What’s Driving Mazda Limited Stock’s Recent Momentum Key TrendsSector Performance Drivers & Explosive Profit Growth - earlytimes.in
Market Fear: How strong is Protalix BioTherapeutics Inc DE stock earnings growthWeekly Trade Recap & Community Trade Idea Sharing - Bộ Nội Vụ
Protalix BioTherapeutics (AMEX: PLX)Related Research - intelligentinvestor.com.au
Protalix BioTherapeutics (NYSE:PLX) CEO Buys $101,360.00 in Stock - MarketBeat
Bashan Dror, Protalix BioTherapeutics CEO, buys $101k in shares By Investing.com - Investing.com Canada
Protalix BioTherapeutics (PLX) CEO and director reports 56,000-share stock purchase - Stock Titan
PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration - Research Tree
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration - Zacks Small Cap Research
How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Opening Moves & Community Verified Trade Alerts - Улправда
Will Protalix BioTherapeutics Inc. (DE) stock outperform Dow JonesWeekly Gains Summary & Entry Point Strategy Guides - DonanımHaber
Can Protalix BioTherapeutics Inc. stock beat analyst upgradesWeekly Gains Summary & Verified Entry Point Detection - Улправда
Institution Moves: Is Protalix BioTherapeutics Inc. stock a contrarian buyBond Market & Community Verified Trade Signals - Улправда
Is Protalix BioTherapeutics Inc. (DE) stock a buy before new product rolloutJuly 2025 Institutional & Reliable Price Breakout Alerts - DonanımHaber
Sentiment Review: Is Protalix BioTherapeutics Inc. stock attractive for hedge fundsJuly 2025 Volume & High Win Rate Trade Tips - Улправда
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3%Still a Buy? - MarketBeat
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3% – Still a Buy? - Defense World
Breakout Zone: How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Technicals & AI Forecast for Swing Trade Picks - Улправда
Is Protalix BioTherapeutics Inc. stock a contrarian buy2025 Big Picture & Technical Pattern Based Buy Signals - Улправда
Protalix and Secarna partner to develop rare kidney disease treatments By Investing.com - Investing.com South Africa
Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development - Proactive financial news
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - Finviz
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Protalix BioTherapeutics (PLX) Partners with Secarna for Kidney Disorder Treatments - GuruFocus
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter Into Collaboration and Option Agreement - 富途牛牛
Protalix Partners With Secarna to Jointly Develop Therapies for Rare Renal Indications - marketscreener.com
Protalix and Secarna partner to develop rare kidney disease treatments - Investing.com
Protalix BioTherapeutics Inc. (PLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):